[{"address1": "3 Temasek Avenue", "address2": "Level 18 Centennial Tower", "city": "Singapore", "zip": "039190", "country": "Singapore", "phone": "65 6817 9598", "website": "https://aslanpharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.", "fullTimeEmployees": 34, "companyOfficers": [{"maxAge": 1, "name": "Dr. Carl Alan Jason Morton Firth EMBA, Ph.D.", "age": 50, "title": "Founder, CEO & Executive Director", "yearBorn": 1973, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Kiran Kumar  Asarpota", "age": 44, "title": "COO & Head of Finance", "yearBorn": 1979, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ben  Goodger", "age": 60, "title": "General Counsel", "yearBorn": 1963, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stephen  Doyle", "age": 50, "title": "Chief Business Officer", "yearBorn": 1973, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Alexandre  Kaoukhov M.D.", "age": 49, "title": "Chief Medical Officer", "yearBorn": 1974, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Charlie  Hsu", "title": "Investor Relations Director", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Chi-Chin  Wang", "title": "IR & Corporate Development Director", "exercisedValue": 0, "unexercisedValue": 0}], "maxAge": 86400, "priceHint": 4, "previousClose": 0.5816, "open": 0.611, "dayLow": 0.611, "dayHigh": 0.7419, "regularMarketPreviousClose": 0.5816, "regularMarketOpen": 0.611, "regularMarketDayLow": 0.611, "regularMarketDayHigh": 0.7419, "beta": 1.49, "forwardPE": -0.15741177, "volume": 199758, "regularMarketVolume": 199758, "averageVolume": 241333, "averageVolume10days": 305560, "averageDailyVolume10Day": 305560, "bid": 0.62, "ask": 0.695, "bidSize": 1100, "askSize": 1400, "marketCap": 11153903, "fiftyTwoWeekLow": 0.392, "fiftyTwoWeekHigh": 4.69, "priceToSalesTrailing12Months": 0.92949194, "fiftyDayAverage": 0.5707, "twoHundredDayAverage": 1.73578, "currency": "USD", "enterpriseValue": 247630656, "floatShares": 350071207, "sharesOutstanding": 16672500, "sharesShort": 31325, "sharesShortPriorMonth": 53660, "sharesShortPreviousMonthDate": 1705017600, "dateShortInterest": 1707955200, "sharesPercentSharesOut": 0.0019, "heldPercentInsiders": 0.00052, "heldPercentInstitutions": 0.14896, "shortRatio": 0.19, "shortPercentOfFloat": 0.0019, "bookValue": -0.051, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -45188256, "trailingEps": -3.0, "forwardEps": -4.25, "enterpriseToRevenue": 20.636, "enterpriseToEbitda": -5.595, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "ASLN", "underlyingSymbol": "ASLN", "shortName": "ASLAN Pharmaceuticals Limited", "longName": "ASLAN Pharmaceuticals Limited", "firstTradeDateEpochUtc": 1525440600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "64d5d950-3f7f-30f1-9c3d-4a28bad97a03", "gmtOffSetMilliseconds": -18000000, "currentPrice": 0.669, "targetHighPrice": 17.0, "targetLowPrice": 15.0, "targetMeanPrice": 16.0, "targetMedianPrice": 16.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 40817976, "totalCashPerShare": 0.095, "ebitda": -44260632, "totalDebt": 38327124, "quickRatio": 1.946, "currentRatio": 2.111, "totalRevenue": 12000000, "revenuePerShare": 0.769, "returnOnAssets": -0.47210997, "returnOnEquity": -4.26641, "grossMargins": 1.0, "operatingMargins": -3.69022, "financialCurrency": "USD", "trailingPegRatio": null}]